|
1
|
Mattiuzzi C, Lippi G. Evidence of concerning decline of COVID-19 vaccination in older persons. Immunol Res 2024:10.1007/s12026-024-09460-1. [PMID: 38277057 DOI: 10.1007/s12026-024-09460-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Accepted: 01/24/2024] [Indexed: 01/27/2024]
Affiliation(s)
- Camilla Mattiuzzi
- Medical Direction, Rovereto Hospital, Service of Clinical Governance and Medical Direction, Provincial Agency for Social and Sanitary Services (APSS), Trento, Italy
| | - Giuseppe Lippi
- Section of Clinical Biochemistry, University of Verona, Piazzale L.A. Scuro, 10, 37134, Verona, Italy.
| |
Collapse
|
|
2
|
Awasthi M, Macaluso A, Myscofski D, Prigge J, Koide F, Noyce RS, Fogarty S, Stillwell H, Goebel SJ, Daugherty B, Nasar F, Bavari S, Lederman S. Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates. Vaccines (Basel) 2023; 11:1682. [PMID: 38006014 PMCID: PMC10674175 DOI: 10.3390/vaccines11111682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Revised: 10/27/2023] [Accepted: 10/30/2023] [Indexed: 11/26/2023] Open
Abstract
TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. TNX-1800 vaccination was well tolerated with no serious adverse events or significant changes in clinical parameters. A single dose of TNX-1800 generated humoral responses in African Green Monkeys and Cynomolgus Macaques, as measured by the total binding of anti-SARS-CoV-2 S IgG and neutralizing antibody titers against the USA-WA1/2020 strain. In addition, a single dose of TNX-1800 induced an interferon-gamma (IFN-γ)-mediated T-cell response in Cynomolgus Macaques. Following challenge with SARS-CoV-2, African Green and Cynomolgus Macaques exhibited rapid clearance of virus in the upper and lower respiratory tract. Future studies will assess the efficacy of TNX-1800 against newly emerging variants and demonstrate its safety in humans.
Collapse
Affiliation(s)
- Mayanka Awasthi
- Tonix Pharmaceuticals, Frederick, MD 21701, USA; (M.A.); (A.M.); (D.M.); (S.J.G.); (F.N.); (S.B.)
| | - Anthony Macaluso
- Tonix Pharmaceuticals, Frederick, MD 21701, USA; (M.A.); (A.M.); (D.M.); (S.J.G.); (F.N.); (S.B.)
| | - Dawn Myscofski
- Tonix Pharmaceuticals, Frederick, MD 21701, USA; (M.A.); (A.M.); (D.M.); (S.J.G.); (F.N.); (S.B.)
| | | | | | - Ryan S. Noyce
- Department of Medical Microbiology & Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2R3, Canada;
| | | | - Helen Stillwell
- Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA;
- Tonix Pharmaceuticals, Chatham, NJ 07928, USA;
| | - Scott J. Goebel
- Tonix Pharmaceuticals, Frederick, MD 21701, USA; (M.A.); (A.M.); (D.M.); (S.J.G.); (F.N.); (S.B.)
| | | | - Farooq Nasar
- Tonix Pharmaceuticals, Frederick, MD 21701, USA; (M.A.); (A.M.); (D.M.); (S.J.G.); (F.N.); (S.B.)
| | - Sina Bavari
- Tonix Pharmaceuticals, Frederick, MD 21701, USA; (M.A.); (A.M.); (D.M.); (S.J.G.); (F.N.); (S.B.)
| | | |
Collapse
|